C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

J. Lauwyck, A. Beckwee, A. Santens, J. K. Schwarze, G. Awada, V. Vandersleyen, S. Aspeslagh, B. Neyns

Research output: Contribution to journalMeeting abstract (Journal)

Original languageEnglish
Pages (from-to)S759-S759
JournalAnnals of Oncology
Volume31
DOIs
Publication statusPublished - Sep 2020
EventESMO Virtual Congress -
Duration: 19 Sep 202018 Oct 2020

Keywords

  • C-reactive protein
  • Biomarker
  • melanoma

Cite this